Burning Rock Biotech Limited
No trades
No trades
Compare with Burning Rock Biotech Limited
−0.91 USD
−7.70 M USD
75.06 M USD
8.76 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Yu Sheng Han
Website
Headquarters
Guangzhou
Founded
2014
IPO date
Jun 12, 2020
ISIN
US12233L2060
CUSIP
12233L206
FIGI
BBG00V1JWDY7
Identifiers
ISIN US12233L2060
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.
BNR Possible 10-20% profitAlthough BNR is looking bearish on the SMA and MACD indicators, we do see on the RSI that BNR is currently oversold...
The RSI alone is making me bullish on a quick 10-20% profit because the stock can retrace to an upper support level.
This is purely speculative however, as it is entire possible t
BNR is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Burning Rock Biotech Limited focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
Oscillators
Neutral
Summary
Neutral
Summary
Neutral
Summary
Neutral
Moving Averages
Neutral
Moving Averages
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.





